Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, d

Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, d

Item
http://www.wikidata.org/entity/Q44824319
Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of RodentsThe P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondiiRecent advances in pharmacokinetic extrapolation from preclinical data to humans.Brain distribution and bioavailability of elacridar after different routes of administration in the mouse.Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.The blood-brain barrier in migraine treatment.A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC.Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics.Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.Tumor stressors induce two mechanisms of intracellular p-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones.
P2860

Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, d

Item
http://www.wikidata.org/entity/Q44824319
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@en
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@nl
type
label
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@en
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@nl
prefLabel
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@en
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P356
P1433
P1476
Preclinical pharmacokinetic pr ...... boxamide) in the mouse, rat, d
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698